Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

PR NewswireMarch 17, 2025

Tag: Rona Therapeutics , IND , RN0361 , siRNA , APOC3

PharmaSources Customer Service